This study is testing a combination of two drugs, cabozantinib and pembrolizumab, for people with advanced adrenal cortical cancer. Adrenal cortical cancer is a type of cancer that starts in the outer layer of the adrenal gland and can spread to other parts of the body. Cabozantinib targets and blocks receptors on cancer cells, which may help stop the cancer from growing and spreading. Pembrolizumab is an immunotherapy drug that helps the immune system attack cancer cells. The study aims to see how well these drugs work together. **Key Points:** - **Duration and Visits**: Treatment cycles are 21 days long, with repeat cycles until the cancer progresses or there are unacceptable side effects. Follow-up lasts up to 2 years. - **Tests and Procedures**: Participants will need regular imaging tests like CT or MRI scans and provide blood samples. A tissue biopsy might be required at the start. - **Eligibility**: Participants must be 18 or older with a specific health status and may have had prior treatments. Certain health conditions and medications could exclude participation. Participants will be closely monitored, and the study involves both taking oral medication and receiving intravenous treatment.